Ascend Capital’s AstraZeneca AZN Stock Holding History

Ascend Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-359,773	Closed	-$22.4M	–	154
2017 Q1	$22.4M	Sell	359,773 -243,832	-40%	-$14.2M	1.01%	39
2016 Q4	$33M	Buy	603,605 +463,087	+330%	+$26.3M	1.64%	16
2016 Q3	$9.23M	Buy	140,518 +27,032	+24%	+$1.77M	0.57%	63
2016 Q2	$6.85M	Buy	+113,486	New	+$6.59M	0.45%	81
2015 Q1	–	Sell	-201,565	Closed	-$14.2M	–	170
2014 Q4	$14.2M	Buy	+201,565	New	+$14.4M	0.54%	64

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Ascend Capital's AZN Position: Q2 2017 in Review

Ascend Capital sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 359,773 shares — an estimated $22.4M sold.

Ascend Capital first reported a position in AZN in Q4 2014 and held it in 5 quarters. The position peaked at $33M in Q4 2016. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

Ascend Capital reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
Ascend Capital sold 359,773 AstraZeneca shares in Q2 2017, an estimated $22.4M.
Ascend Capital first reported a position in AstraZeneca in Q4 2014 and held it in 5 quarters.
Ascend Capital's AstraZeneca position peaked at $33M in Q4 2016.
466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on Ascend Capital's 13F filing for Q2 2017, filed 11 Aug 2017.